<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Granulomatosis with polyangiitis and microscopic polyangiitis: Management of relapsing disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Granulomatosis with polyangiitis and microscopic polyangiitis: Management of relapsing disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Granulomatosis with polyangiitis and microscopic polyangiitis: Management of relapsing disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ronald J Falk, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter A Merkel, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard J Glassock, MD, MACP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gerald B Appel, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albert Q Lam, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Philip Seo, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 16, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H4048150543">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are related systemic small-vessel vasculitides. Both are associated with antineutrophil cytoplasmic autoantibodies (ANCA) and have similar histologic features on kidney biopsy (eg, a focal necrotizing, pauci-immune, crescentic glomerulonephritis). They have somewhat different clinical features, serologic findings, and outcomes, including different patterns of pulmonary involvement and relapse rates. These entities are closely related to kidney-limited pauci-immune necrotizing and crescentic glomerulonephritis.
        </p>
        <p>
         Relapsing disease refers to recurrence of signs or symptoms of active vasculitis in any organ system after remission is achieved, in the absence of another cause.
        </p>
        <p>
         The management of relapsing GPA or MPA will be reviewed here. Clinical manifestations and diagnosis, initial therapy, and the management of treatment-resistant disease are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3071.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Management of disease resistant to initial therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1321073498">
         <span class="h1">
          DEFINITION OF RELAPSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         A clinical relapse is defined by the presence of both of the following [
         <a href="#rid1">
          1,2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The recurrence of signs or symptoms of active vasculitis in any organ system after remission is achieved (see
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Definitions of response'
         </a>
         ). Examples of recurrence include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An active urine sediment (dysmorphic [glomerular] hematuria with or without red cell casts), which may be accompanied by a rise in serum creatinine
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hemoptysis or pulmonary hemorrhage or new or expanding pulmonary nodules in the absence of evidence of infection
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Iritis or uveitis, mononeuritis multiplex, rhinitis, sinusitis, any of several types of skin lesions, or necrotizing vasculitis on biopsy of any tissue
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Such signs or symptoms are judged to be due to active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) and not to another cause. As an example, not all instances of new hematuria or pulmonary nodules in a patient with GPA or MPA are due to active vasculitis. This differentiation between manifestations of active vasculitis and manifestations of another process can sometimes be difficult. (See
         <a class="local">
          'Diagnosis of relapse'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H610321700">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H3271798443">
         <span class="h2">
          Rates of relapse
         </span>
         <span class="headingEndMark">
          —
         </span>
         The reported rates of relapse vary widely among studies, ranging from approximately 10 to 60 percent [
         <a href="#rid1">
          1-9
         </a>
         ]. This wide range of reported relapse rates may be due at least in part to differences in induction or maintenance therapy, the proportion of patients with anti-proteinase-3 (PR3) antineutrophil cytoplasmic autoantibody (ANCA) serotype (PR3-ANCA) versus anti-myeloperoxidase (MPO) ANCA serotype (MPO-ANCA) or that of granulomatosis with polyangiitis (GPA) versus microscopic polyangiitis (MPA), the duration of follow-up, and the criteria used to define relapse. The following examples are illustrative:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a community-based cohort in which 258 patients attained remission, 109 (42 percent) relapsed. Patients who were anti-PR3 seropositive were nearly twice as likely to relapse as compared with patients who were anti-MPO seropositive, suggesting that patients with PR3-ANCA are more likely to relapse than those with MPO-ANCA [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'Risk factors for relapse'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a randomized trial comparing daily oral versus intravenous pulse
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         for initial immunosuppressive therapy, the relapse rate at a median of 4.3 years was greater in the intravenous pulse group (40 versus 21 percent), suggesting that difference of therapy may affect relapse rates [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among patients in the
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         in ANCA-Associated Vasculitis (RAVE) trial who attained a complete remission, relapse occurred in approximately 30 percent at 18 months [
         <a href="#rid5">
          5
         </a>
         ]. The relapse rate was higher among those with PR3- as compared with MPO-ANCA, with GPA as compared with MPA, and with a prior history of relapsing disease (approximately one-half of all patients in the study).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2178846579">
         <span class="h2">
          Risk factors for relapse
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following have been identified as risk factors for relapse:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seropositivity for PR3-ANCA
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior history of relapsing disease
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Involvement of the lung prior to remission
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Involvement of the upper respiratory tract prior to remission
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Persistence of elevated ANCA titers, particularly PR3-ANCA, and rising ANCA titers
        </p>
        <p>
        </p>
        <p>
         The association of PR3-ANCA seropositivity, lung involvement, and upper respiratory tract involvement with the risk of relapse was evaluated in a community-based cohort study of 350 patients with newly diagnosed ANCA-associated vasculitis who were followed for a median of four years [
         <a href="#rid1">
          1
         </a>
         ]. The rate of relapse was much higher in patients with all three of these risk factors compared with those who had none (73 percent at a median of 17 months versus 26 percent at a median of 62 months; the median time to relapse was 15 and 20 months, respectively). Other cohorts have confirmed a higher relapse rate in patients with lung involvement and in those with PR3-ANCA [
         <a href="#rid5">
          5,9-13
         </a>
         ].
        </p>
        <p>
         Relapses are also more common in patients with GPA, occurring in 25 to 80 percent of patients, than in those with MPA, in whom relapse has been reported in 8 percent at 18 months and 30 to 35 percent at four to seven years [
         <a href="#rid1">
          1,5,14,15
         </a>
         ]. Why relapses are more common in GPA is not well understood. Proposed mechanisms include persistent granulomata [
         <a href="#rid16">
          16
         </a>
         ] and persistent PR3 expression on the membrane of neutrophils [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         In addition, chronic nasal carriage of
         <em>
          Staphylococcus aureus
         </em>
         is associated with relapse [
         <a href="#rid18">
          18,19
         </a>
         ], although flares in such patients are not related to active staphylococcal infection [
         <a href="#rid18">
          18
         </a>
         ]. The mechanisms by which
         <em>
          S. aureus
         </em>
         might act are not understood but may involve the staphylococcal toxic shock syndrome toxin-1 or changes in the nasal microbiome [
         <a href="#rid19">
          19-21
         </a>
         ].
        </p>
        <p>
         A history of prior flares greatly increases the risk of a subsequent flare compared with patients who have never flared. Such patients are often treated with more prolonged maintenance therapy.
        </p>
        <p class="headingAnchor" id="H2711287795">
         <span class="h2">
          Precipitants of relapse
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infections have been hypothesized to trigger some disease flares by inducing expression of the ANCA antigens (PR3 and MPO) on the surface of circulating neutrophils. This can, in the presence of ANCA, lead to neutrophil degranulation, the release of oxygen radicals, and vascular injury [
         <a href="#rid16">
          16
         </a>
         ]. In addition, the interaction between the nasal microbiome and disease activity remains an area of active investigation [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3060.html" rel="external">
          "Clinical spectrum of antineutrophil cytoplasmic autoantibodies"
         </a>
         .)
        </p>
        <p>
         Discontinuation of glucocorticoids may also be associated with a greater risk of flare [
         <a href="#rid22">
          22
         </a>
         ]. However, the severity of such relapses is not clear, since reemergence of minor symptoms may often be easily treated with resumption of low-dose glucocorticoids. The role of low-dose glucocorticoids and duration of glucocorticoid dosing in the treatment of GPA and MPA are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Glucocorticoid dosing and taper'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3579765485">
         <span class="h1">
          ESTABLISHING RELAPSING DISEASE
         </span>
        </p>
        <p class="headingAnchor" id="H3904930714">
         <span class="h2">
          Monitoring for relapse
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regular, indefinite follow-up and monitoring is needed even for patients in remission for several years. Most relapses of granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) occur within the first 12 to 18 months after the cessation of immunosuppressive therapy [
         <a href="#rid1">
          1,2,23,24
         </a>
         ] and may or may not affect the same organ as the initial presentation [
         <a href="#rid2">
          2,3,25
         </a>
         ]; however, relapses can occur more than 10 years after the initial presentation or a prior relapse. The majority of relapses are discovered early and are limited in nature in patients who are closely followed and who have been educated about their disease and when to report new symptoms.
        </p>
        <p class="headingAnchor" id="H4063421914">
         <span class="h3">
          Patient self-monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early detection of relapse before severe tissue injury has occurred is an important component of monitoring since reinduction of remission can usually be attained more quickly. Patients should be evaluated promptly if they develop new or increasing hematuria or any other clinical manifestations.
        </p>
        <p>
         The primary components of patient self-monitoring include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient education about the clinical manifestations of relapse, which include active lung disease (eg, cough, dyspnea, wheezing, hemoptysis), neurologic disease (eg, muscle weakness, numbness, hearing loss, headache), skin disease (purpura, nodules, ulcerations), upper respiratory tract manifestations (eg, sinusitis, otitis media, nasal ulcers and crusting, and/or subglottic disease), or general symptoms (fevers, fatigue, arthritis/arthralgias, weight loss). (See
         <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The use of urine dipsticks every one to two months or more frequently at home in patients who had kidney involvement prior to achieving remission. Urine dipstick monitoring at home may also be of value in patients without a history of kidney disease since manifestations of a relapse may differ from those of the initial presentation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If there is recurrent hematuria with or without proteinuria, the urine should be tested again in four to seven days (since transient hematuria can occur from other causes), and if the dipstick is still positive for heme and/or protein, the patient should be evaluated without delay.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A potential confounding issue can occur in premenopausal patients who often have blood in the urine due to contamination from menstrual bleeding. Thus, for premenopausal patients, testing should be performed at least a few days before or after their menstrual period. (See
         <a class="medical medical_review" href="/z/d/html/7208.html" rel="external">
          "Etiology and evaluation of hematuria in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It is important to recognize that persistent hematuria in patients with GPA or MPA is associated with an increased risk of relapse, but patients can have persistent hematuria for extended periods of time in the absence of active vasculitis, and not all recurrent hematuria is necessarily due to vasculitis [
         <a href="#rid26">
          26
         </a>
         ]. Thus, screening for hematuria is advisable, but positive findings should lead to appropriate clinical evaluation and not an automatic decision to change or initiate immunosuppressive therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prompt communication with the treating clinician if any new signs or symptoms of disease occur.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1070157500">
         <span class="h3">
          Monitoring by the clinician
         </span>
         <span class="headingEndMark">
          —
         </span>
         Assuming that the patient is self-monitoring and remains asymptomatic, and that screening urine dipstick testing does not reveal hematuria, we follow patients in the office at one- to three-month intervals during the first year after remission has been induced and then every three to four months thereafter. During each visit, we perform the following evaluation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessment for signs or symptoms of active disease (see
         <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis", section on 'Clinical manifestations'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Measurement of serum creatinine, electrolytes, and aminotransferases
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urinalysis with examination of the urinary sediment
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Spot urine protein-to-creatinine ratio
        </p>
        <p>
        </p>
        <p>
         The practice of measuring antineutrophil cytoplasmic autoantibody (ANCA) titers during follow-up visits varies among clinicians. This is largely because ANCA titers are
         <strong>
          not
         </strong>
         a reliable marker of disease activity. A reasonable approach is to closely follow patients with rising ANCA titers but not to alter their therapy unless there are clear clinical signs of active disease. Some experts measure an ANCA titer when a patient attains remission and then repeat the titer if a flare is suspected. Others monitor ANCA at regular intervals, and patients who have a rise in serum ANCA titers are monitored more frequently for early signs of clinical relapse. Some expert centers do not monitor ANCA titers at all. However, patients should
         <strong>
          not
         </strong>
         be treated for relapse based solely upon ANCA titers.
        </p>
        <p>
         While some observational data suggest serum ANCA titers appear to parallel the course of vasculitis in some patients [
         <a href="#rid13">
          13,27-30
         </a>
         ], other studies, including some larger cohort studies, have found that a rise in ANCA titer is not consistently predictive of a disease flare, with discordant ANCA titers and disease activity occurring in as many as 60 percent of patients [
         <a href="#rid23">
          23,24,27,31-37
         </a>
         ]. The best data come from a meta-analysis of nine studies that examined the association of a rise in ANCA titer (or persistently positive ANCA titers) during remission with likelihood of relapse [
         <a href="#rid38">
          38
         </a>
         ]. As a predictor of relapse, a rise in ANCA titer had a sensitivity of 56 percent and a specificity of 82 percent; a persistently positive titer had a sensitivity of 38 percent and a specificity of 78 percent. Thus, rising titers or persistently positive titers are not likely to be sufficiently reliable to guide therapeutic decisions.
        </p>
        <p>
         If a patient was ANCA positive during a period of active disease, a persistently ANCA-negative status is consistent with, but not absolute proof of, remission. The same meta-analysis that examined the value of persistently positive ANCA titers discussed above also analyzed the value of persistently negative titers and found that this scenario should not lead to a change in therapy [
         <a href="#rid38">
          38
         </a>
         ]. Similarly, another study reported that 37 of 100 patients with ANCA-associated vasculitis suffered flares during the period of observation [
         <a href="#rid27">
          27
         </a>
         ]. Of these, three (8 percent) were ANCA negative at the time of relapse.
        </p>
        <p class="headingAnchor" id="H2042322631">
         <span class="h2">
          Diagnosis of relapse
         </span>
         <span class="headingEndMark">
          —
         </span>
         A diagnosis of relapsing disease is made if there is recurrence of signs or symptoms of active vasculitis in any organ system [
         <a href="#rid1">
          1,2
         </a>
         ]. In some cases, relapse can be diagnosed clinically if the patient has systemic symptoms and the same organ involvement as the initial presentation [
         <a href="#rid14">
          14,25
         </a>
         ]. In other patients, tissue biopsy may be required to verify recurrent vasculitis rather than other factors such as infection.
        </p>
        <p>
         It is important to recognize that, if any presumed disease-related manifestation of GPA or MPA does not respond to reinstitution or escalation of immunosuppressive therapy, the cause of the manifestations should be reevaluated, possibly with a tissue biopsy.
        </p>
        <p>
         Disease flares typically involve the same organs that were affected at the time of initial presentation [
         <a href="#rid3">
          3
         </a>
         ], although new manifestations of disease are not uncommon [
         <a href="#rid25">
          25
         </a>
         ]. Thus, diagnosing relapse of GPA or MPA is not always straightforward, and alternative diagnoses must be excluded:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differentiating disease activity from damage
         </strong>
         – It is important for clinicians and patients to differentiate disease-associated "activity" from disease-associated "damage" in GPA and MPA. Damage is the result of prior activity and is generally considered permanent and not reversible with immunosuppression. Examples of damage that can mimic active disease in GPA and MPA are chronic rhinosinusitis, a scarred pulmonary nodule, or chronic proteinuria or some cases of progressive kidney disease. Tissue biopsy may sometimes be required to determine if a manifestation is due to active disease, prior damage, or another disease process.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Relapsing upper respiratory tract disease versus infection
         </strong>
         – Patients treated with glucocorticoids,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , and other therapies for ANCA-associated vasculitis remain immunosuppressed for significant periods following the cessation of these medications, thereby increasing the risk for infection. Infections are particularly important to exclude in patients with respiratory tract disease. It may be difficult, for example, to distinguish between active disease and infection (and some patients have both) in patients who develop manifestations limited to the upper respiratory tract, such as nasal ulcers and crusting. Endoscopic examination by an experienced ear, nose, and throat clinician may establish a definitive diagnosis but often shows only nonspecific acute and chronic inflammation. (See
         <a class="medical medical_review" href="/z/d/html/4330.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Respiratory tract involvement"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Relapsing glomerulonephritis versus nonimmunologic progression of chronic kidney disease
         </strong>
         – Late progression of kidney disease, as defined by a rise in serum creatinine, is common. However, such progression does not necessarily imply active renal vasculitis, since two nonimmunologic mechanisms may be important in the absence of active disease:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Glomerular ischemia and subsequent glomerulosclerosis resulting from progressive narrowing of the vascular lumens during the healing phase of the vasculitis
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Secondary hemodynamic and metabolic factors induced by nephron loss, such as intraglomerular hypertension in the remaining functioning glomeruli (see
         <a class="medical medical_review" href="/z/d/html/7181.html" rel="external">
          "Secondary factors and progression of chronic kidney disease"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with nonimmunologic progression have slowly progressive disease characterized by gradual increases in the serum creatinine concentration and proteinuria, which is usually subnephrotic but can reach the nephrotic range. Both hypoalbuminemia and edema are unusual, even when protein excretion exceeds 3 to 4 g/day.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with nonimmunologic progression should not have an active urinary sediment (eg, red cells and cellular casts) or other signs of disease activity; such findings may indicate relapsing ANCA-associated glomerulonephritis, although persistent hematuria can be present and not be associated with active vasculitis [
         <a href="#rid26">
          26
         </a>
         ]. However, some renal "relapses," characterized by acutely worsening kidney function and hematuria, are not due to reactivation of GPA or MPA but rather to a distinct second form of glomerulonephritis, such as immunoglobulin A (IgA) nephropathy [
         <a href="#rid39">
          39-41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lower respiratory tract disease versus malignancy or infection
         </strong>
         – The appearance of a new pulmonary nodule may be due to recurrent vasculitis, especially if there is contemporaneous appearance of other disease-related manifestations. However, clinicians should always be concerned that the nodule may be due to infection or malignancy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1728567909">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goal of managing relapsing disease is reinduction and maintenance of complete remission, which is the absence of any signs of active disease. The definition of complete remission in patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) is discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Definitions of response'
         </a>
         and
         <a class="local">
          'Monitoring for relapse'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3397372597">
         <span class="h2">
          Organ- or life-threatening relapse
         </span>
         <span class="headingEndMark">
          —
         </span>
         Severe relapses are usually treated with reinstitution of induction therapy followed by maintenance therapy.
        </p>
        <p class="headingAnchor" id="H498158867">
         <span class="h3">
          Reinduction therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who relapse after successfully achieving remission with a cyclophosphamide-based or a rituximab-based regimen, we suggest readministering induction therapy with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         rather than
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         . This regimen is discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Rituximab-based regimen'
         </a>
         .)
        </p>
        <p>
         Data from randomized trials suggest that
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         is at least as effective for treating disease relapses and may also be associated with less cumulative toxicity compared with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         . Rituximab is also the preferred agent in women who wish to preserve their potential to conceive a child.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          Cyclophosphamide
         </a>
         is a reasonable alternative for patients whose relapse is characterized by advanced and progressive crescentic glomerulonephritis or severe pulmonary disease with massive hemorrhage. However, there are no trial data to guide the choice between cyclophosphamide and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         in such patients. In addition, some experts treat such patients with
         <strong>
          both
         </strong>
         cyclophosphamide and rituximab (eg, four weekly infusions of rituximab plus two intravenous pulses of cyclophosphamide) [
         <a href="#rid42">
          42-44
         </a>
         ].
        </p>
        <p>
         Most trials on remission induction in GPA and MPA do not distinguish between those patients treated for a new or relapsing presentation of their disease, and the evidence for new or relapsing disease comes from the same studies. One of the larger trials to distinguish patients with relapsing disease randomly assigned 101 patients with relapsing GPA or MPA to either
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         or
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         [
         <a href="#rid5">
          5,45
         </a>
         ]. The majority of patients had received cyclophosphamide for initial induction therapy or prior relapse (74 percent of the cyclophosphamide group and 82 percent of the rituximab group). The rate of remission induction in these patients with relapsing disease at six months was higher with rituximab (67 versus 42 percent; odds ratio 1.40, 95% CI 1.03-1.91) [
         <a href="#rid45">
          45
         </a>
         ]. At 18 months, however, rituximab and cyclophosphamide produced similar remission rates in these patients, and there were no differences in the number of adverse events [
         <a href="#rid5">
          5
         </a>
         ]. In another prospective study of 188 patients with relapsing GPA or MPA who were treated with rituximab plus glucocorticoids, 171 (90 percent) achieved remission by four months [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         If patients cannot tolerate
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         or
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , we attempt to achieve remission with
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil (MMF). (See
         <a class="local">
          'Patients who have multiple relapses'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3008080016">
         <span class="h3">
          Maintenance therapy after reinduction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Relapse can occur while patients are being treated with maintenance therapy or after maintenance therapy has been discontinued [
         <a href="#rid1">
          1
         </a>
         ]. The choice of drug and the duration of maintenance therapy after reinduction of remission are determined in part by the timing of relapse:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Relapse during maintenance therapy
         </strong>
         – For patients who exhibit a severe relapse while on the original course of maintenance therapy, we suggest using a different drug for maintenance therapy after reinduction of remission. In such patients, the duration of maintenance therapy may be similar to that suggested for the original course of maintenance therapy (usually 12 to 18 months, but this can vary with the estimated likelihood of relapse).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The usual drugs for maintenance therapy are
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         , and in patients with an estimated glomerular filtration rate (eGFR) above 60 mL/min/1.73 m
         <sup>
          2
         </sup>
         and no renal vasculitis,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         . MMF is an alternative agent for patients who do not respond to, cannot tolerate, or have contraindications to these drugs.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Dosing of rituximab'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Dosing of azathioprine'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Dosing of methotrexate'
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Dosing of mycophenolate'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Glucocorticoid therapy is part of the maintenance immunosuppression regimen. The median duration of glucocorticoid therapy after the first induction of remission is less than six to eight months. Some experts recommend long-term, low-dose maintenance therapy in patients who have had multiple relapses. (See
         <a class="local">
          'Patients who have multiple relapses'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Relapse after maintenance therapy
         </strong>
         – For patients who relapse after the discontinuation of the original course of maintenance therapy, we suggest using the same drug for maintenance therapy after remission has been reinduced. However, the duration should be longer than the initial course (eg, 12 months or longer if the original course of maintenance therapy was 6 to 12 months). For patients who have frequent relapses, lifelong maintenance therapy may be appropriate, similar to that in recipients of organ transplants. (See
         <a class="local">
          'Patients who have multiple relapses'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         The approach to maintenance therapy is extrapolated from data in patients receiving maintenance therapy for new-onset disease and our clinical experience. A discussion of the relevant data is presented in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Choice of maintenance therapy'
         </a>
         .)
        </p>
        <p>
         There is some evidence that
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         is an effective maintenance drug for the prevention of relapses limited to the upper respiratory tract. However, toxicity is an issue, since in the randomized trial suggesting benefit compared with placebo in this setting, 20 percent of patients treated with trimethoprim-sulfamethoxazole maintenance discontinued therapy due to side effects, most of which are minor (anorexia, nausea, rash) [
         <a href="#rid47">
          47
         </a>
         ]. In addition, high-dose trimethoprim-sulfamethoxazole cannot be used in patients receiving
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         and should be used cautiously in patients with advanced chronic kidney disease.
        </p>
        <p class="headingAnchor" id="H2685621920">
         <span class="h2">
          Non-organ- and non-life-threatening relapse
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to the treatment of a mild, non-organ-threatening relapse varies, depending upon whether the relapse occurs while the patient was still receiving maintenance therapy (see
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Non-organ- and non-life-threatening disease'
         </a>
         ). A non-organ-threatening relapse includes patients with recurrent dysmorphic hematuria who do not have in increase in serum creatinine:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Relapse during maintenance therapy
         </strong>
         – For patients who develop a non-organ- and non-life-threatening relapse while still receiving maintenance therapy, we suggest increasing the dose of glucocorticoids and, when relevant, increasing the dose of the immunosuppressive agent used for maintenance therapy. In a patient receiving tapering doses of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         and
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , for example, the prednisone dose can temporarily be increased back to 60 mg/day (although lower starting doses may also be adequate), and the methotrexate dose can be increased back to 25 mg once weekly.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When the clinician is unsure that a relapse is mild, a tissue biopsy should be obtained to confirm that reinduction therapy is not needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Relapse after maintenance therapy
         </strong>
         – For patients who develop a non-organ- and non-life-threatening relapse after maintenance therapy has been discontinued, we suggest reinstitution of the prior maintenance therapy in combination with a short course of glucocorticoids. However, maintenance therapy should be continued for a longer period of time than was given prior to the relapse (eg, 12 to 18 months if the original course of maintenance therapy was 6 to 12 months).
        </p>
        <p>
        </p>
        <p>
         There are limited data to guide the optimal therapy of patients with a non-organ- and non-life-threatening disease relapse, and our approach is largely based on clinical experience and observational data. One observational study of 44 patients with their first non-severe relapse found that treatment with a temporary increase in the glucocorticoid dose restored disease remission in most patients (80 percent), but recurrent relapses occurred in the majority of patients by approximately 12 months [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2090424191">
         <span class="h2">
          Specific clinical scenarios
         </span>
        </p>
        <p class="headingAnchor" id="H1856614074">
         <span class="h3">
          Patients who have multiple relapses
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who have multiple relapses despite treatment with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         and/or
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , or who cannot tolerate these therapies, can be treated with MMF.
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          Azathioprine
         </a>
         and
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         (in patients with an eGFR above 60 mL/min/1.73 m
         <sup>
          2
         </sup>
         and no renal vasculitis) are reasonable alternatives and may be preferred based on other patient-specific factors. Dosing of these agents is discussed in detail elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Dosing of mycophenolate'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Dosing of methotrexate'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Dosing of azathioprine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The potential efficacy of MMF was illustrated in a series of 32 patients with relapsing antineutrophil cytoplasmic autoantibody (ANCA)-positive vasculitis who could not be treated with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         [
         <a href="#rid49">
          49
         </a>
         ]. Complete and partial remissions were achieved in 78 and 19 percent, respectively. Relapse during follow-up occurred in 19 of 25 patients (76 percent) who attained complete remission and in all six who attained partial remission. Patients who had previously been treated successfully with cyclophosphamide had a better response than those who had not (complete remission was 84 versus 50 percent; relapse was 50 versus 100 percent). The median time to relapse was similar to the previous median time to relapse (16 versus 17 months), and all but two patients were still taking MMF at the time of relapse. The other two patients relapsed after MMF had been discontinued (at 16 and 41 months) and were successfully treated with a second course of MMF and
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         .
        </p>
        <p class="headingAnchor" id="H49200153">
         <span class="h3">
          Relapses limited to the upper airway
         </span>
         <span class="headingEndMark">
          —
         </span>
         It may be difficult to distinguish between active disease and infection (and some patients have both) when the manifestations of possible relapse are limited to the upper respiratory tract, particularly with nasal disease, where ulceration and crusting over granulation tissue can result from both vasculitis and infection. (See
         <a class="local">
          'Diagnosis of relapse'
         </a>
         above.)
        </p>
        <p>
         The therapeutic approach varies with the presumed diagnosis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When infection is thought to be the predominant problem, oral antibiotics are often required (eg,
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         ). However, some prefer topical
         <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">
          mupirocin
         </a>
         ointment for less severe infections. The ointment can be applied directly inside of each nostril or mixed into a
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         irrigation solution. Topical antibiotics have the advantage of permitting a long course of therapy without the systemic side effects that may be seen with oral antibiotics. (See
         <a class="medical medical_review" href="/z/d/html/83012.html" rel="external">
          "Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment", section on 'Antibiotics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When active vasculitis is thought to be the predominant problem and the relapse is limited to the upper respiratory tract, we increase the
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         dose for at least four weeks and continue or increase the dose of the drug used for maintenance immunosuppression.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When possible, we avoid treating for infection and active vasculitis simultaneously since this leads to diagnostic confusion and possibly to overexposure to medication.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1261029293">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110250.html" rel="external">
          "Society guideline links: Glomerular disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H26699023">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition of relapse
         </strong>
         – In patients with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), relapsing disease refers to recurrence of signs or symptoms of active vasculitis in any organ system after remission is achieved, in the absence of another cause. (See
         <a class="local">
          'Definition of relapse'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring for relapse
         </strong>
         – All patients with GPA or MPA should have regular, indefinite follow-up and monitoring. Patient self-monitoring may include the use of urine dipsticks every one to two months or more frequently at home in patients who had kidney involvement prior to achieving remission. Routine monitoring by the clinician includes assessment for signs and symptoms of active disease; measurement of serum creatinine, electrolytes, and aminotransferases; complete blood count; urinalysis with examination of the urinary sediment; and spot urine protein-to-creatinine ratio. (See
         <a class="local">
          'Monitoring for relapse'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis of relapse
         </strong>
         – A diagnosis of relapsing disease is made if there is recurrence of signs or symptoms of active vasculitis in any organ system. In some cases, relapse can be diagnosed clinically if the patient has systemic symptoms and the same organ involvement as the initial presentation. In other patients, tissue biopsy is required to verify recurrent vasculitis rather than other factors such as infection. Diagnosing relapse of GPA or MPA is not always straightforward, and alternative diagnoses must be excluded. (See
         <a class="local">
          'Diagnosis of relapse'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of relapse
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Organ- or life-threatening relapse
         </strong>
         – Patients with organ- or life-threatening relapse are usually treated with reinstitution of induction therapy followed by maintenance therapy:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients who relapse after successfully achieving remission with a cyclophosphamide-based or a rituximab-based regimen, we suggest readministering induction therapy with
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         rather than
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Reinduction therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients who exhibit a severe relapse while on the original course of maintenance therapy, we suggest using a different drug for maintenance therapy after reinduction of remission rather than the same drug (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In such patients, the duration of maintenance therapy may be similar to that suggested for the original course of maintenance therapy (usually 12 to 18 months, but this can vary with the estimated likelihood of relapse). The usual drugs for maintenance therapy are
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil (MMF), and in patients with an estimated glomerular filtration rate (eGFR) above 60 mL/min/1.73 m
         <sup>
          2
         </sup>
         and no renal vasculitis,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients who relapse after the discontinuation of the original course of maintenance therapy, we suggest using the same drug for maintenance therapy after remission has been reinduced (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The duration of maintenance therapy should be longer than the initial course (eg, 12 months or longer if the original course of maintenance therapy was 6 to 12 months). For patients who have frequent relapses, lifelong maintenance therapy may be appropriate, similar to that in recipients of organ transplants. (See
         <a class="local">
          'Maintenance therapy after reinduction'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">
          "Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Choice of maintenance therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Non-organ- and non-life-threatening relapse
         </strong>
         – Our approach to the treatment of a mild, non-organ-threatening relapse varies, depending upon whether the relapse occurred while the patient was still receiving maintenance therapy:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients who develop a non-organ- and non-life-threatening relapse while still receiving maintenance therapy, we suggest increasing the dose of glucocorticoids and, when relevant, increasing the dose of the immunosuppressive agent used for maintenance therapy rather than switching to another therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients who develop a non-organ- and non-life-threatening relapse after maintenance therapy has been discontinued, we suggest reinstitution of the prior maintenance therapy in combination with a short course of glucocorticoids (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Maintenance therapy should be continued for a longer period of time than was given prior to the relapse (eg, 12 to 18 months if the original course of maintenance therapy was 6 to 12 months). (See
         <a class="local">
          'Non-organ- and non-life-threatening relapse'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Multiple relapses
         </strong>
         – Patients who have multiple relapses despite treatment with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         and/or
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , or who cannot tolerate these therapies, can be treated with MMF.
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          Azathioprine
         </a>
         and
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         are reasonable alternatives and may be preferred depending on patient-specific factors. (See
         <a class="local">
          'Patients who have multiple relapses'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H781726918">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges John H Stone, MD, MPH, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Hogan SL, Falk RJ, Chin H, et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005; 143:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996; 7:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen M, Yu F, Zhao MH. Relapses in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: likely to begin with the same organ as initial onset. J Rheumatol 2008; 35:448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012; 71:955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013; 369:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savage CO, Winearls CG, Evans DJ, et al. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med 1985; 56:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reinhold-Keller E, Fink CO, Herlyn K, et al. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002; 47:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lionaki S, Blyth ER, Hogan SL, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 2012; 64:3452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagnoux C, Hogan SL, Chin H, et al. Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum 2008; 58:2908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cao Y, Tian Z, Li W, et al. Predictors of treatment resistance and relapse in Chinese patients with antineutrophil cytoplasmic antibody-associated disease. J Rheumatol 2014; 41:916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miloslavsky EM, Specks U, Merkel PA, et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2013; 65:2441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kemna MJ, Damoiseaux J, Austen J, et al. ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease. J Am Soc Nephrol 2015; 26:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gayraud M, Guillevin L, le Toumelin P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44:666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bacon PA. The spectrum of Wegener's granulomatosis and disease relapse. N Engl J Med 2005; 352:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rarok AA, Stegeman CA, Limburg PC, Kallenberg CG. Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. J Am Soc Nephrol 2002; 13:2232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stegeman CA, Tervaert JW, Sluiter WJ, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Intern Med 1994; 120:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Popa ER, Tervaert JW. The relation between Staphylococcus aureus and Wegener's granulomatosis: current knowledge and future directions. Intern Med 2003; 42:771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Popa ER, Stegeman CA, Abdulahad WH, et al. Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. Rheumatology (Oxford) 2007; 46:1029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rhee RL, Sreih AG, Najem CE, et al. Characterisation of the nasal microbiota in granulomatosis with polyangiitis. Ann Rheum Dis 2018; 77:1448.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. Arthritis Care Res (Hoboken) 2010; 62:1166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geffriaud-Ricouard C, Noël LH, Chauveau D, et al. Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients. Clin Nephrol 1993; 39:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jayne DR, Gaskin G, Pusey CD, Lockwood CM. ANCA and predicting relapse in systemic vasculitis. QJM 1995; 88:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grayson PC, Cuthbertson D, Carette S, et al. New features of disease after diagnosis in 6 forms of systemic vasculitis. J Rheumatol 2013; 40:1905.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rhee RL, Davis JC, Ding L, et al. The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. Clin J Am Soc Nephrol 2018; 13:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000; 43:2025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Han WK, Choi HK, Roth RM, et al. Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis. Kidney Int 2003; 63:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fussner LA, Hummel AM, Schroeder DR, et al. Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3. Arthritis Rheumatol 2016; 68:1700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Göçeroğlu A, Berden AE, Fiocco M, et al. ANCA-Associated Glomerulonephritis: Risk Factors for Renal Relapse. PLoS One 2016; 11:e0165402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kyndt X, Reumaux D, Bridoux F, et al. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med 1999; 106:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pettersson E, Heigl Z. Antineutrophil cytoplasmic antibody (cANCA and pANCA) titers in relation to disease activity in patients with necrotizing vasculitis: a longitudinal study. Clin Nephrol 1992; 37:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finkielman JD, Merkel PA, Schroeder D, et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007; 147:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerr GS, Fleisher TA, Hallahan CW, et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 1993; 36:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaskin G, Savage CO, Ryan JJ, et al. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant 1991; 6:689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tervaert JW, Huitema MG, Hené RJ, et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990; 336:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russell KA, Fass DN, Specks U. Antineutrophil cytoplasmic antibodies reacting with the pro form of proteinase 3 and disease activity in patients with Wegener's granulomatosis and microscopic polyangiitis. Arthritis Rheum 2001; 44:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomasson G, Grayson PC, Mahr AD, et al. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis. Rheumatology (Oxford) 2012; 51:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrassy K, Waldherr R, Erb A, Ritz E. De novo glomerulonephritis in patients during remission from Wegener's granulomatosis. Clin Nephrol 1992; 38:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haas M, Jafri J, Bartosh SM, et al. ANCA-associated crescentic glomerulonephritis with mesangial IgA deposits. Am J Kidney Dis 2000; 36:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bantis C, Stangou M, Schlaugat C, et al. Is presence of ANCA in crescentic IgA nephropathy a coincidence or novel clinical entity? A case series. Am J Kidney Dis 2010; 55:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGregor JG, Hogan SL, Kotzen ES, et al. Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant 2015; 30 Suppl 1:i123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pendergraft WF 3rd, Cortazar FB, Wenger J, et al. Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis. Clin J Am Soc Nephrol 2014; 9:736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith RM, Jones RB, Specks U, et al. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis 2020; 79:1243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 1996; 335:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miloslavsky EM, Specks U, Merkel PA, et al. Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids. Arthritis Rheumatol 2015; 67:1629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stassen PM, Tervaert JW, Stegeman CA. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 2007; 66:798.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3040 Version 37.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16263884" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8808107" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Treatment response and relapse in antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18085730" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Relapses in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: likely to begin with the same organ as initial onset.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22128076" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23902481" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Efficacy of remission-induction regimens for ANCA-associated vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15673801" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Etanercept plus standard therapy for Wegener's granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4048389" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Microscopic polyarteritis: presentation, pathology and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12115164" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23023777" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18759282" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24634200" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Predictors of treatment resistance and relapse in Chinese patients with antineutrophil cytoplasmic antibody-associated disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23754238" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25324502" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12840090" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11263782" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15673799" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The spectrum of Wegener's granulomatosis and disease relapse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12191967" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8250451" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14518661" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The relation between Staphylococcus aureus and Wegener's granulomatosis: current knowledge and future directions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17409134" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29997110" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Characterisation of the nasal microbiota in granulomatosis with polyangiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20235186" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7681736" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7704563" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : ANCA and predicting relapse in systemic vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23908447" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : New features of disease after diagnosis in 6 forms of systemic vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29371340" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11014352" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12631091" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26882078" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27973575" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : ANCA-Associated Glomerulonephritis: Risk Factors for Renal Relapse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10335724" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1351434" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Antineutrophil cytoplasmic antibody (cANCA and pANCA) titers in relation to disease activity in patients with necrotizing vasculitis: a longitudinal study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17975183" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8452581" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1754104" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1975893" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11229478" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Antineutrophil cytoplasmic antibodies reacting with the pro form of proteinase 3 and disease activity in patients with Wegener's granulomatosis and microscopic polyangiitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22039267" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1468158" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : De novo glomerulonephritis in patients during remission from Wegener's granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11007672" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : ANCA-associated crescentic glomerulonephritis with mesangial IgA deposits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20042261" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Is presence of ANCA in crescentic IgA nephropathy a coincidence or novel clinical entity? A case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25805743" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20647198" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24626432" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20647199" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32581088" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8637536" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25776953" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17179175" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
